Atossa Therapeutics Inc

ATOSNASDAQ · USD
1.75USD0.00 (-3.32%)
152

Atossa Therapeutics Inc (ATOS) Covered Calls

Atossa Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 43.25%, average versus the past year. ATOS's highest covered call setup is the $2.00 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 5.26% out of the money with 59 days to expiration, a 10.53% return until expiration, and a 65.12% theoretical annualized return. Across the setups shown, annualized returns run from 25.61% to 65.12% at strikes between $2.00 and $2.00, with 59 to 150 days to expiration, as of Nov 17, 2026.

Read more

Running ATOS covered calls helps you generate income from Atossa Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ATOS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ATOS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ATOS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ATOS covered call is worth writing.

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc.

2027-01-15592.005.260.100.3020.0010.5365.12-5.26+0.511400.20
2027-04-161502.005.260.101.1020.0010.5325.61-5.26+0.6501.00

As of Nov 17, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank43.25% Moderate
  • Market cap (M$)17
  • 52 weeks high-88.22%
  • 52 weeks low2.94%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$19.00
    985.71% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-10
  • P/E—
  • Future P/E—
  • EPS (ttm)-3.90
  • EPS growth next 5 years—

As of Nov 18, 2026